Table 2 Lymphocyte subsets in health control and liver steatosis group.
From: Peripheral blood lymphocyte subsets of Chinese adults with liver steatosis
Lymphocyte subsets | Normal range | All patients (n = 5042) | Control group (n = 3601) | Liver steatosis group (n = 1441) | p value | Median difference |
|---|---|---|---|---|---|---|
CD19+ percentage, % | 8.5–14.5 | 11.0 (8.4–13.9) | 10.9 (8.3–13.7) | 11.3 (8.5–14.4) | 0.016 | − 3.0 (− 6.0 to − 1.0) |
CD19+ count, /μL | 180–324 | 190 (138–261) | 183 (134–250) | 209 (149–282) | < 0.001 | − 23 (− 29 to − 17) |
CD16+56+ percentage, % | 9.5–23.5 | 13.9 (9.7–19.8) | 13.9 (9.7–19.7) | 13.9 (9.9–19.9) | 0.296 | − 0.2 (− 0.7 to 0.2) |
CD16+56+ count, /μL | 175–567 | 241 (161–359) | 236 (155–350) | 257 (176–381) | < 0.001 | − 24 (− 32 to − 15) |
CD3+ percentage, % | 62.6–76.8 | 73.3 (67.3–78.3) | 73.5 (67.4–78.4) | 72.8 (67.2–77.9) | 0.047 | 0.5 (0.0 to 1.0) |
CD3+ count, /μL | 1185–1901 | 1268 (1029–1551) | 1239 (1007–1516) | 1346 (1103–1632) | < 0.001 | − 105 (− 129 to − 81) |
CD4+ percentage, % | 30.0–46.0 | 41.0 (35.5–46.5) | 41.0 (35.4–46.4) | 41.3 (35.9–46.6) | 0.278 | − 0.3 (− 0.8 to 0.2) |
CD4+ count, /μL | 561–1137 | 708 (563–890) | 689 (547–861) | 754 (605–956) | < 0.001 | − 68 (− 83 to − 53) |
CD4+CD28+/CD4+, % | 85.0–100.0 | 96.6 (92.2–98.8) | 96.6 (92.2–98.8) | 96.6 (92.3–98.8) | 0.745 | 0.0 (− 0.2 to 0.2) |
CD4+CD28+ count, /μL | 520–1050 | 664 (523–840) | 647 (512–810) | 710 (568–899) | < 0.001 | − 64 (− 79 to − 50) |
CD4+CD45RA−/CD4+, % | 45.6–68.4 | 70.4 (60.9–79.5) | 70.3 (60.7–79.3) | 70.9 (61.5–80.1) | 0.090 | − 0.7 (− 1.6 to 0.1) |
CD4+CD45RA− count, /μL | 283–683 | 487 (379–615) | 469 (368–594) | 528 (409–666) | < 0.001 | − 53 (− 63 to − 42) |
CD4+CD45RA+/CD4+, % | 31.6–54.4 | 29.6 (20.5–39.1) | 29.7 (20.8–39.3) | 29.1 (19.9–38.5) | 0.086 | 0.7 (− 0.1 to 1.6) |
CD4+CD45RA+ count, /μL | 206–530 | 203 (126–303) | 198 (125–294) | 216.0 (131.0–320.5) | 0.001 | − 13 (− 20 to − 5) |
CD4+CD45RA+62L+/CD4+, % | 31.6–54.4 | 27.7 (18.8–37.3) | 27.8 (18.8–37.5) | 27.6 (18.5–36.8) | 0.228 | 0.5 (− 0.3 to 1.3) |
CD4+CD45RA+62L+ count, /μL | 206–530 | 190 (116–287) | 186 (115–280) | 202 (120–306) | 0.001 | − 13 (− 20 to − 6) |
CD8+ percentage, % | 19.2–33.6 | 24.5 (19.9–29.9) | 24.6 (19.9–30.0) | 24.5 (19.9–29.7) | 0.583 | 0.1 (− 0.3 to 0.6) |
CD8+ count, /μL | 404–754 | 432 (317–568) | 420 (310–556) | 453 (341–601) | < 0.001 | − 34 (− 45 to − 23) |
CD8+CD28+/CD8+, % | 37.2–60.4 | 60.9 (48.7–72.8) | 61.3 (48.7–73.0) | 59.5 (48.7–71.9) | 0.065 | 1.0 (− 0.1 to 2.1) |
CD8+CD28+ count, /μL | 190–392 | 250 (184–332) | 244 (180–328) | 263 (197–344) | < 0.001 | − 18 (− 24 to − 11) |
CD8+DR+/CD8+, % | 6.3–23.8 | 34.3 (24.2–45.1) | 33.5 (23.5–44.2) | 35.9 (26.1–46.9) | < 0.001 | − 2.3 (− 3.2 to − 1.4) |
CD8+DR+ count, /μL | 20–178 | 138 (88–211) | 131 (82.8–202) | 158 (101–236) | < 0.001 | − 21 (− 27 to − 16) |
CD8+CD38+/CD8+, % | 32.4–57.4 | 30.8 (22.3–40.7) | 31.3 (22.4–41.1) | 29.8 (21.9–39.8) | 0.005 | 1.1 (0.3 to 1.9) |
CD8+CD38+ count, /μL | 157–385 | 126 (84–189) | 124 (83–189) | 130 (87–191) | 0.015 | − 5.4 (− 9.8 to − 1.1) |
CD4+/CD8+, % | 0.95–2.13 | 1.66 (1.26–2.23) | 1.66 (1.24–2.23) | 1.67 (1.28–2.22) | 0.446 | − 0.02 (− 0.06 to 0.03) |
